Lenvatinib
Showing 1 - 25 of 454
Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer Trial in Shanghai (Lenvatinib Oral Product Plus VIC1911)
Not yet recruiting
- Liver Cancer
- +2 more
- Lenvatinib Oral Product Plus VIC1911
-
Shanghai, ChinaDeparment of Liver Surgery, Ren Ji Hospital, School of Medicine,
Jan 30, 2023
Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)
Not yet recruiting
- Liver Diseases
- +4 more
- bTAE-HAIC
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 30, 2023
GBM Trial (Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields))
Not yet recruiting
- GBM
- Lenvatinib
- +2 more
- (no location specified)
Aug 2, 2023
Hepatocellular Carcinoma Trial in Seoul (Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib
-
Seoul, Korea, Republic ofAsan Medical Center
Nov 14, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jul 12, 2023
Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Recruiting
- Solid Tumor, Adult
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Sep 13, 2023
Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib plus sintilimab, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Lenvatinib plus sintilimab
- Lenvatinib
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022
Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, sintilimab plus SIRT)
Not yet recruiting
- Hepatocellular Carcinoma
- Lenvatinib, sintilimab plus SIRT
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Aug 8, 2023
Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Lenvatinib Plus I-125 Seed Brachytherapy
- Lenvatinib
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022
Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib Plus Tislelizumab
- Transarterial Chemoembolization(TACE)
-
Beijing, Beijing, ChinaNan Zhang
Apr 22, 2023
Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)
Not yet recruiting
- Potentially Resectable Hepatocellular Carcinoma
- (no location specified)
Nov 16, 2023
Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)
Not yet recruiting
- Hepatocellular Carcinoma
- Cryoablation
- +2 more
- (no location specified)
May 31, 2023
Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)
Not yet recruiting
- Liver Diseases
- +4 more
- bTAE-HAIC
- +2 more
-
Guanzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 24, 2023
Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)
Not yet recruiting
- Endometrial Cancer
- Endometrial Adenocarcinoma
- Cadonilimab
- Lenvatinib
-
Guangzhou, ChinaSun Yat-sen University Cancer Cetntre
Apr 9, 2023
PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,
Not yet recruiting
- PD-1 Refractory Advanced Melanoma
- Responder-Derived Fecal microbiota transplantation (R-FMT
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 1, 2023
Hepatocellular Carcinoma Trial (TACE(transcatheter arterial chemoembolization), lenvatinib, Icaritin soft capsules)
Not yet recruiting
- Hepatocellular Carcinoma
- TACE(transcatheter arterial chemoembolization)
- +2 more
- (no location specified)
Jun 5, 2023
Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)
Recruiting
- Unresectable Hepatocellular Carcinoma
- D-TACE
- +3 more
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Oct 14, 2022
Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab, Lenvatinib
- (no location specified)
Mar 29, 2023
Advanced Hepatocellular Carcinoma Trial in Chengdu (Lenvatinib combined with TACE and Camrelizumab)
Recruiting
- Advanced Hepatocellular Carcinoma
- Lenvatinib combined with TACE and Camrelizumab
-
Chengdu, Sichuan, ChinaHuaXi hospital
Feb 12, 2023
Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)
Not yet recruiting
- Breast Neoplasms
- Sindilimab
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiangCH
Nov 17, 2023
Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)
Not yet recruiting
- Gastric Cancer Metastatic to Liver
- Cryoablation
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 6, 2023
Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)
Recruiting
- Cadonilimab
- +2 more
- Cadonilimab Combined With Lenvatinib
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen University Cancer Center
Nov 16, 2023
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head Neck Cancer Trial in United States (Lenvatinib
Completed
- Head and Neck Squamous Cell Carcinoma
- +3 more
- Lenvatinib Pill
- Cetuximab
-
Basking Ridge, New Jersey
- +6 more
Oct 13, 2022
Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))
Not yet recruiting
- Hepatocellular Carcinoma
- Sintilimab
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023